Prasugrel, a third generation thienopyridine and potent platelet inhibitor.

Published

Journal Article (Review)

Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the treatment of thromboembolism in patients with ischemic strokes or acute coronary syndromes. The companies were expected to launch the drug in the US by the end of 2008.

Full Text

Pubmed Central version
Link to Item

Duke Authors

Gurbel, Paul Alfred

Cited Authors

Gurbel, PA; Tantry, US

Published Date

March 2008

Published In

Current Opinion in Investigational Drugs (London, England : 2000)

Volume / Issue

9 / 3

Start / End Page

324 - 336

PubMed ID

18311669

Pubmed Central ID

18311669

International Standard Serial Number (ISSN)

1472-4472

Language

Conference Location

England